Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(0.96) per share which missed the analyst consensus estimate of $(0.69) by 39.13 percent. This is a 1.05 percent decrease over losses of $(0.95) per share from the same period last year.
Regulation Fears Grip Bitcoin, Ethereum Dip Attracts Buyers, Dogecoin Declines Sharply — Here’s What To Watch For In This Correction
Major coins saw a deep correction Thursday and continued to trade in the red at press time as the global cryptocurrency market cap sank 5.58% to $2.51 trillion.
